Pharmafile Logo

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

First, we need to talk: mental healthcare in the MENA region

In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

ESOMAR Asia Pacific 2018

13-15 May, Bangkok

Intellus Worldwide Summit 2018

Visit us on stand number 413

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Conducting market research for scientific publication guide

Conducting and using market research for publication can be valuable for shaping opinions in healthcare. The findings can be used to influence existing perceptions, change current practices and behaviour in...

Therapy Watch appoints new Associate Director

Research Partnership has appointed Mark Hollis to join the Therapy Watch team as Associate Director. Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA...

Sabera Hyderally appointed Head of MedTech North America

Research Partnership is delighted to welcome Sabera Hyderally who has joined the company’s US headquarters in Philadelphia.